INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.75
+4.17%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1B | 3.2B | 4.9M | 4.6M | 4.1M |
| Cost of Revenue | 1.8B | 2.5B | 3.2M | 3.5M | 2.7M |
| Gross Profit | 306.8M | 709.8M | 1.7M | 1.1M | 1.4M |
| Operating Expenses | |||||
| R&D Expense | 775.8M | 15.1M | 2.9M | 3.2M | 3.7M |
| SG&A Expense | 3.7B | 1.9B | 6.6M | 5.8M | 5.8M |
| General & Admin Expense | 3.7B | 1.9B | 6.6M | 5.8M | 5.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (4.4B) | (1.9B) | 212.8K | 219.6K | 202.2K |
| Total Operating Expenses | 10.5M | 9.2M | 9.6M | 9.2M | 9.8M |
| Cost and Expenses | 12.1M | 9.9M | 12.9M | 12.7M | 12.5M |
| Operating Income (EBIT) | (10.9M) | (9.9M) | (7.9M) | (8.1M) | (8.4M) |
| Non-Operating | |||||
| Interest Income | 165.5K | 245.0K | 156.5K | 722.0K | 652.4K |
| Interest Expense | 10.7K | 10.7K | 373.1K | — | — |
| Net Interest Income | 154.8K | 234.3K | (216.6K) | 722.0K | 652.4K |
| Other Non-Op Income/Expense | (1.5M) | (1.5M) | (244.1K) | 466.0K | 444.3K |
| Non-Operating Income (excl Interest) | (101.7K) | — | (127.4K) | (466.0K) | (444.3K) |
| EBT (Pre-Tax Income) | (12.4M) | (11.4M) | (8.2M) | (7.7M) | (7.9M) |
| Income Tax Expense | — | — | — | 7.1K | 13.1K |
| Bottom Line | |||||
| Net Income | (2.3B) | (12.6M) | (8.2M) | (7.7M) | (7.9M) |
| Earnings from Cont. Ops | (12.4M) | (11.4M) | (8.2M) | (7.7M) | (7.9M) |
| Earnings from Discont. Ops | (1.2M) | (1.2M) | — | — | — |
| Bottom Line Net Income | (2.3B) | (13.0M) | (8.2M) | (7.7M) | (7.9M) |
| Per Share | |||||
| Basic EPS | ($3.30) | ($3.12) | ($8.36) | ($20.14) | ($64.92) |
| Diluted EPS | ($3.30) | ($3.12) | ($8.36) | ($20.14) | ($64.92) |
| Revenue Per Share | $376.44 | $762.92 | $5.06 | $12.07 | $33.78 |
| Shares | |||||
| Basic Shares Outstanding | 5.5M | 4.2M | 975985 | 381053 | 122422 |
| Diluted Shares Outstanding | 5.5M | 4.2M | 975985 | 381053 | 122422 |
| Profitability Metrics | |||||
| EBITDA | (10.0M) | (9.2M) | (7.3M) | (7.1M) | (7.3M) |
| D&A | 772.7K | 708.4K | 534.7K | 604.5K | 596.0K |
| EBIT | (10.8M) | (9.9M) | (7.8M) | (7.7M) | (7.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026